Estrone Sulfate (37104X)

Test Code

153551P

CPT Codes
82679

Preferred Specimen

0.5 mL serum

Minimum Volume

0.3 mL

Other Acceptable Specimens

Plasma collected in: EDTA (lavender-top) tube

Transport Temperature

Room temperature

Specimen Stability

Room temperature: 5 days
Refrigerated: 21 days
Frozen -20° C: 1 year
Frozen -70° C: 1 year

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Moderate to gross hemolysis • Grossly lipemic

Methodology
Chromatography/Mass Spectrometry

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Night

Clinical Significance

This test measures serum concentration of estrone sulfate, an endogenous estrogen that can convert to estrone and estradiol. Estrone sulfate has been investigated as a potential biomarker for several estrogen-associated malignancies, such as breast cancer, endometrial cancer, ovarian cancer, and prostate cancer [1].

Estrone sulfate is the most abundant circulating estrogen in nonpregnant persons. Although biologically inactive, estrone sulfate is a precursor of estrone, which can be converted to estradiol, the most potent estrogen in nonpregnant persons. In children, men, and postmenopausal women, low levels of estradiol may not be measured accurately. Therefore, estrone sulfate measurement may have the potential to serve as a substitute biomarker when estrogens levels are low but have clinical significance [1].

The clinical application of estrone sulfate measurement was explored in numerous studies but has not been well-established. As a potential marker in estrogen-associated malignancies, estrone sulfate has been investigated in risk assessment of breast cancer, proliferation of endometrial cancer, and prognosis of advanced prostatic carcinoma [1]. In addition, estrone sulfate levels may help evaluate treatment effectiveness of aromatase inhibitors and steroid sulfatase inhibitors in patients with breast cancer [1].

Estrone sulfate levels may be affected by exogenous estrogens, such as contraceptives, hormone replacement therapy medications, conjugated equine estrogens, and aromatase inhibitors [1].

The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.

Reference
1. Rezvanpour A, et al. Crit Rev Clin Lab Sci. 2017;54(2):73-86.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.